Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 12/20 | 0.62 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.60 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
| ▸ | F7 | P08709 | 1/20 | 0.58 |
| ▸ | F3 | P13726 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5891883 | 0.82 | PYGL (0.67) | PYGLNHERF1HRH4HRH3F7 | |
| SCHEMBL13753365 | 0.81 | ALOX15 (0.79) | PYGLNHERF1HRH4HRH3F7 | |
| SCHEMBL5869825 | 0.81 | PYGL (0.56) | PYGLNHERF1HRH4HRH3 | |
| SCHEMBL5869858 | 0.81 | PYGL (0.56) | PYGLNHERF1HRH4HRH3 | |
| SCHEMBL5869836 | 0.81 | PYGL (0.56) | PYGLNHERF1HRH4HRH3 | |
| SCHEMBL18766925 | 0.79 | NHERF1 (0.79) | PYGLNHERF1HRH4HRH3EGFR | |
| SCHEMBL27709059 | 0.79 | HRH4 (0.55) | PYGLNHERF1HRH4HRH3F7 | |
| SCHEMBL4933623 | 0.79 | F7 (0.66) | PYGLNHERF1HRH4HRH3F7 | |
| SCHEMBL6162686 | 0.78 | PYGL (0.65) | PYGLNHERF1HRH4HRH3 | |
| SCHEMBL17149781 | 0.78 | NHERF1 (0.88) | PYGLNHERF1HRH4HRH3F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846820-B2 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-6649634-B2 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| CN-1098838-C | Substituted N- (indole-2-carbonyl) -beta-alaninamides and derivatives as antidiabetics | PFIZER (US) | 2003-01-15 | — | — | CN | disclosed |
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | HOOVER DENNIS J (US) | 2002-03-07 | — | — | US | disclosed |
| US-6297269-B1 | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors | PFIZER INC. | 2001-10-02 | — | — | US | disclosed |
| EP-0832066-B1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-0832066-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| CN-1140709-A | Substituted N- (indole-2-carbonyl) -beta-alaninamides and derivatives as antidiabetics | PFIZER (US) | 1997-01-22 | — | — | CN | disclosed |
| WO-1996039385-A1 | SUBSTITUTED N-(INDOLE-2-CARBONYL-) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS | PFIZER INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028810-A1 | Use in treating diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | PYGL 1/4885NHERF1 821/4885HRH4 962/4885 |
| US-20040006088-A1 | For therapy of diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemias, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals | PYGL, GPR119, PYGM | PYGL 1/4885NHERF1 690/4885HRH4 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.